在该公司报告季度损失之后,Akebia治疗局内部人员出售了大量股份。 Akebia Therapeutics insiders sold significant shares, following the company's reported quarterly loss.

2月3日, Akebia 治疗内幕者Nicholas Grund和Steven Keith Burke出售股票,Grund出售55 621股,Burke出售50 506股,所有权分别下降了11.16%和5.83%。 Akebia Therapeutics insiders Nicholas Grund and Steven Keith Burke sold shares on February 3rd, with Grund selling 55,621 shares and Burke selling 50,506 shares, representing ownership decreases of 11.16% and 5.83%, respectively. 该公司最近报告说,每股季度损失0.10美元,缺少分析师的估计数。 The company recently reported a quarterly loss of $0.10 per share, missing analyst estimates. Akebia正在为治疗肾病病人的贫血症开发Vafseo。 Akebia is developing Vafseo for treating anemia in kidney disease patients.